Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public OfferingGlobeNewsWire • 05/22/23
New Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in Heart Failure OutcomesGlobeNewsWire • 05/18/23
New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart FailureGlobeNewsWire • 04/20/23
Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring'23 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic (BVA-100®)GlobeNewsWire • 04/17/23
Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific SessionsGlobeNewsWire • 04/13/23
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure PatientsGlobeNewsWire • 03/27/23
New Study Confirms Daxor's BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure PatientsGlobeNewsWire • 03/23/23
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022GlobeNewsWire • 03/02/23
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care CongressGlobeNewsWire • 01/13/23
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment OptionGlobeNewsWire • 11/17/22
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public OfferingGlobeNewsWire • 11/15/22
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific MeetingGlobeNewsWire • 10/05/22
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL'22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR'S BLOOD VOLUME DIAGNOSTIC (BVA-100®)GlobeNewsWire • 10/04/22
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided CareGlobeNewsWire • 10/03/22
Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of AmericaGlobeNewsWire • 09/26/22
Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022GlobeNewsWire • 08/25/22
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate UpdateGlobeNewsWire • 08/24/22
DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICEGlobeNewsWire • 06/27/22